Download PDF
Semin Liver Dis 2010; 30(4): 391-401
DOI: 10.1055/s-0030-1267539
© Thieme Medical Publishers

Novel Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease

Ariel E. Feldstein1 , 2 , 3
  • 1Department of Cell Biology, Lerner Research Institute Cleveland Clinic College of Medicine of CWRU, Cleveland Clinic, Cleveland, Ohio
  • 2Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
  • 3Department of Pediatric Gastroenterology, Cleveland Clinic, Cleveland, Ohio
Further Information

Publication History

Publication Date:
19 October 2010 (online)

    Permissions and Reprints

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is currently the most common form of chronic liver disease affecting both adults and children in the United States and many other parts of the world. NAFLD encompasses a wide spectrum of conditions associated with overaccumulation of lipids in the liver. It is strongly associated with obesity and insulin resistance and has been growingly recognized as an independent risk factor for cardiovascular disease. In this review, recently uncovered novel aspects of the molecular events responsible for the development and progression of this highly prevalent and potentially serious disease are discussed. These studies bring new insights that may significantly impact the clinical approach to patients with NAFLD, from novel diagnostics to innovative therapeutic strategies.

KEYWORDS

Lipotoxicity - apoptosis - nonalcoholic fatty liver disease - steatohepatitis - free fatty acids

REFERENCES

  • 1 Angulo P. Nonalcoholic fatty liver disease.  N Engl J Med. 2002;  346(16) 1221-1231
    CrossrefPubMedGoogle Scholar
  • 2 Wieckowska A, Feldstein A E. Nonalcoholic fatty liver disease in the pediatric population: a review.  Curr Opin Pediatr. 2005;  17(5) 636-641
    CrossrefPubMedGoogle Scholar
  • 3 Brunt E M, Janney C G, Di Bisceglie A M, Neuschwander-Tetri B A, Bacon B R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.  Am J Gastroenterol. 1999;  94(9) 2467-2474
    CrossrefPubMedGoogle Scholar
  • 4 Adams L A, Lymp J F, St Sauver J et al.. The natural history of nonalcoholic fatty liver disease: a population-based cohort study.  Gastroenterology. 2005;  129(1) 113-121
    CrossrefPubMedGoogle Scholar
  • 5 Ekstedt M, Franzén L E, Mathiesen U L et al.. Long-term follow-up of patients with NAFLD and elevated liver enzymes.  Hepatology. 2006;  44(4) 865-873
    CrossrefPubMedGoogle Scholar
  • 6 Browning J D, Horton J D. Molecular mediators of hepatic steatosis and liver injury.  J Clin Invest. 2004;  114(2) 147-152
    CrossrefPubMedGoogle Scholar
  • 7 Donnelly K L, Smith C I, Schwarzenberg S J, Jessurun J, Boldt M D, Parks E J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.  J Clin Invest. 2005;  115(5) 1343-1351
    CrossrefPubMedGoogle Scholar
  • 8 Bieghs V, Wouters K, van Gorp P J et al.. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice.  Gastroenterology. 2010;  138(7) 2477-2486, 2486, e1–e3
    CrossrefPubMedGoogle Scholar
  • 9 Zhou J, Febbraio M, Wada T et al.. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.  Gastroenterology. 2008;  134(2) 556-567
    CrossrefPubMedGoogle Scholar
  • 10 Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.  J Clin Invest. 2008;  118(3) 829-838
    CrossrefPubMedGoogle Scholar
  • 11 Clark J M, Brancati F L, Diehl A M. Nonalcoholic fatty liver disease.  Gastroenterology. 2002;  122(6) 1649-1657
    CrossrefPubMedGoogle Scholar
  • 12 Tilg H, Moschen A R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease.  Trends Endocrinol Metab. 2008;  19(10) 371-379
    CrossrefPubMedGoogle Scholar
  • 13 Shoelson S E, Lee J, Goldfine A B. Inflammation and insulin resistance.  J Clin Invest. 2006;  116(7) 1793-1801
    CrossrefPubMedGoogle Scholar
  • 14 Wellen K E, Hotamisligil G S. Inflammation, stress, and diabetes.  J Clin Invest. 2005;  115(5) 1111-1119
    Google Scholar
  • 15 Tilg H, Moschen A R. Inflammatory mechanisms in the regulation of insulin resistance.  Mol Med. 2008;  14(3-4) 222-231
    PubMedGoogle Scholar
  • 16 Weisberg S P, McCann D, Desai M, Rosenbaum M, Leibel R L, Ferrante Jr A W. Obesity is associated with macrophage accumulation in adipose tissue.  J Clin Invest. 2003;  112(12) 1796-1808
    CrossrefPubMedGoogle Scholar
  • 17 Weisberg S P, Hunter D, Huber R et al.. CCR2 modulates inflammatory and metabolic effects of high-fat feeding.  J Clin Invest. 2006;  116(1) 115-124
    CrossrefPubMedGoogle Scholar
  • 18 Hevener A L, Olefsky J M, Reichart D et al.. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones.  J Clin Invest. 2007;  117(6) 1658-1669
    CrossrefPubMedGoogle Scholar
  • 19 Lumeng C N, Bodzin J L, Saltiel A R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization.  J Clin Invest. 2007;  117(1) 175-184
    CrossrefPubMedGoogle Scholar
  • 20 Hirosumi J, Tuncman G, Chang L et al.. A central role for JNK in obesity and insulin resistance.  Nature. 2002;  420(6913) 333-336
    CrossrefPubMedGoogle Scholar
  • 21 Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil G S. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance.  Proc Natl Acad Sci U S A. 2006;  103(28) 10741-10746
    CrossrefPubMedGoogle Scholar
  • 22 Aguirre V, Uchida T, Yenush L, Davis R, White M F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307).  J Biol Chem. 2000;  275(12) 9047-9054
    CrossrefPubMedGoogle Scholar
  • 23 Sabio G, Das M, Mora A et al.. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance.  Science. 2008;  322(5907) 1539-1543
    CrossrefPubMedGoogle Scholar
  • 24 Kim J Y, van de Wall E, Laplante M et al.. Obesity-associated improvements in metabolic profile through expansion of adipose tissue.  J Clin Invest. 2007;  117(9) 2621-2637
    CrossrefPubMedGoogle Scholar
  • 25 Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice.  Am J Physiol Endocrinol Metab. 2007;  293(4) E1118-E1128
    CrossrefPubMedGoogle Scholar
  • 26 Pang C, Gao Z, Yin J, Zhang J, Jia W, Ye J. Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity.  Am J Physiol Endocrinol Metab. 2008;  295(2) E313-E322
    CrossrefPubMedGoogle Scholar
  • 27 Lauber K, Bohn E, Kröber S M et al.. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal.  Cell. 2003;  113(6) 717-730
    CrossrefPubMedGoogle Scholar
  • 28 Strissel K J, Stancheva Z, Miyoshi H et al.. Adipocyte death, adipose tissue remodeling, and obesity complications.  Diabetes. 2007;  56(12) 2910-2918
    CrossrefPubMedGoogle Scholar
  • 29 Murano I, Barbatelli G, Parisani V et al.. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice.  J Lipid Res. 2008;  49(7) 1562-1568
    CrossrefPubMedGoogle Scholar
  • 30 Cinti S, Mitchell G, Barbatelli G et al.. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans.  J Lipid Res. 2005;  46(11) 2347-2355
    CrossrefPubMedGoogle Scholar
  • 31 Kroemer G, Galluzzi L, Vandenabeele P Nomenclature Committee on Cell Death 2009 et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009.  Cell Death Differ. 2009;  16(1) 3-11
    CrossrefPubMedGoogle Scholar
  • 32 Alkhouri N, Gornicka A, Berk M P et al.. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis.  J Biol Chem. 2010;  285(5) 3428-3438
    CrossrefPubMedGoogle Scholar
  • 33 Guicciardi M E, Gores G J. Life and death by death receptors.  FASEB J. 2009;  23(6) 1625-1637
    CrossrefPubMedGoogle Scholar
  • 34 Wueest S, Rapold R A, Schumann D M et al.. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice.  J Clin Invest. 2010;  120(1) 191-202
    CrossrefPubMedGoogle Scholar
  • 35 Li P, Lu M, Nguyen M T et al.. Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced obese mice.  J Biol Chem. 2010;  285(20) 15333-15345
    CrossrefPubMedGoogle Scholar
  • 36 Day C P, James O F. Steatohepatitis: a tale of two “hits”?.  Gastroenterology. 1998;  114(4) 842-845
    CrossrefPubMedGoogle Scholar
  • 37 Clouston A D, Powell E E. Nonalcoholic fatty liver disease: is all the fat bad?.  Intern Med J. 2004;  34(4) 187-191
    CrossrefPubMedGoogle Scholar
  • 38 Monetti M, Levin M C, Watt M J et al.. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver.  Cell Metab. 2007;  6(1) 69-78
    CrossrefPubMedGoogle Scholar
  • 39 Koliwad S K, Streeper R S, Monetti M et al.. DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation.  J Clin Invest. 2010;  120(3) 756-767
    CrossrefPubMedGoogle Scholar
  • 40 Amaro A, Fabbrini E, Kars M et al.. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia.  Gastroenterology. 2010;  139(1) 149-153
    CrossrefPubMedGoogle Scholar
  • 41 Day C P. The potential role of genes in nonalcoholic fatty liver disease.  Clin Liver Dis. 2004;  8(3) 673-691, xi
    CrossrefPubMedGoogle Scholar
  • 42 Romeo S, Kozlitina J, Xing C et al.. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.  Nat Genet. 2008;  40(12) 1461-1465
    CrossrefPubMedGoogle Scholar
  • 43 He S, McPhaul C, Li J Z et al.. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.  J Biol Chem. 2010;  285(9) 6706-6715
    CrossrefPubMedGoogle Scholar
  • 44 Petersen K F, Dufour S, Hariri A et al.. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.  N Engl J Med. 2010;  362(12) 1082-1089
    CrossrefPubMedGoogle Scholar
  • 45 Alkhouri N, Dixon L J, Feldstein A E. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal.  Expert Rev Gastroenterol Hepatol. 2009;  3(4) 445-451
    CrossrefPubMedGoogle Scholar
  • 46 Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity.  Biochim Biophys Acta. 2010;  1801(3) 299-310
    CrossrefPubMedGoogle Scholar
  • 47 Yamaguchi K, Yang L, McCall S et al.. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.  Hepatology. 2007;  45(6) 1366-1374
    CrossrefPubMedGoogle Scholar
  • 48 Li Z Z, Berk M, McIntyre T M, Feldstein A E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase.  J Biol Chem. 2009;  284(9) 5637-5644
    CrossrefPubMedGoogle Scholar
  • 49 Garcia-Ruiz C, Mari M, Colell A et al.. Mitochondrial cholesterol in health and disease.  Histol Histopathol. 2009;  24(1) 117-132
    PubMedGoogle Scholar
  • 50 Marí M, Colell A, Morales A et al.. Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kappaB activation.  Gastroenterology. 2008;  134(5) 1507-1520
    CrossrefPubMedGoogle Scholar
  • 51 Marí M, Caballero F, Colell A et al.. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis.  Cell Metab. 2006;  4(3) 185-198
    CrossrefPubMedGoogle Scholar
  • 52 Puri P, Baillie R A, Wiest M M et al.. A lipidomic analysis of nonalcoholic fatty liver disease.  Hepatology. 2007;  46(4) 1081-1090
    CrossrefPubMedGoogle Scholar
  • 53 Duncan R E, El-Sohemy A, Archer M C. Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for breast cancer and development.  Mol Nutr Food Res. 2005;  49(2) 93-100
    CrossrefPubMedGoogle Scholar
  • 54 Duncan R E, El-Sohemy A, Archer M C. Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin.  Cancer Lett. 2005;  224(2) 221-228
    CrossrefPubMedGoogle Scholar
  • 55 Caballero F, Fernández A, De Lacy A M, Fernández-Checa J C, Caballería J, García-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH.  J Hepatol. 2009;  50(4) 789-796
    CrossrefPubMedGoogle Scholar
  • 56 Li Z, Yang S, Lin H et al.. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease.  Hepatology. 2003;  37(2) 343-350
    CrossrefPubMedGoogle Scholar
  • 57 Feldstein A E, Canbay A, Guicciardi M E, Higuchi H, Bronk S F, Gores G J. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice.  J Hepatol. 2003;  39(6) 978-983
    CrossrefPubMedGoogle Scholar
  • 58 Tomita K, Tamiya G, Ando S et al.. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice.  Gut. 2006;  55(3) 415-424
    CrossrefPubMedGoogle Scholar
  • 59 Xu A, Wang Y, Keshaw H, Xu L Y, Lam K S, Cooper G J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.  J Clin Invest. 2003;  112(1) 91-100
    CrossrefPubMedGoogle Scholar
  • 60 Crespo J, Cayón A, Fernández-Gil P et al.. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients.  Hepatology. 2001;  34(6) 1158-1163
    CrossrefPubMedGoogle Scholar
  • 61 Hui J M, Hodge A, Farrell G C, Kench J G, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?.  Hepatology. 2004;  40(1) 46-54
    CrossrefPubMedGoogle Scholar
  • 62 Musso G, Gambino R, Durazzo M et al.. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease.  Hepatology. 2005;  42(5) 1175-1183
    CrossrefPubMedGoogle Scholar
  • 63 Abiru S, Migita K, Maeda Y et al.. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis.  Liver Int. 2006;  26(1) 39-45
    CrossrefPubMedGoogle Scholar
  • 64 Kugelmas M, Hill D B, Vivian B, Marsano L, McClain C J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.  Hepatology. 2003;  38(2) 413-419
    PubMedGoogle Scholar
  • 65 Feldstein A E, Werneburg N W, Canbay A et al.. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway.  Hepatology. 2004;  40(1) 185-194
    CrossrefPubMedGoogle Scholar
  • 66 Feldstein A E, Werneburg N W, Li Z, Bronk S F, Gores G J. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization.  Am J Physiol Gastrointest Liver Physiol. 2006;  290(6) G1339-G1346
    CrossrefPubMedGoogle Scholar
  • 67 Li Z, Berk M, McIntyre T M, Gores G J, Feldstein A E. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity.  Hepatology. 2008;  47(5) 1495-1503
    CrossrefPubMedGoogle Scholar
  • 68 Shimomura I, Shimano H, Korn B S, Bashmakov Y, Horton J D. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver.  J Biol Chem. 1998;  273(52) 35299-35306
    CrossrefPubMedGoogle Scholar
  • 69 Shimomura I, Bashmakov Y, Horton J D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus.  J Biol Chem. 1999;  274(42) 30028-30032
    CrossrefPubMedGoogle Scholar
  • 70 Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c).  Exp Biol Med (Maywood). 2007;  232(5) 614-621
    PubMedGoogle Scholar
  • 71 Kaser S, Moschen A, Cayon A et al.. Adiponectin and its receptors in non-alcoholic steatohepatitis.  Gut. 2005;  54(1) 117-121
    CrossrefPubMedGoogle Scholar
  • 72 Moschen A R, Molnar C, Wolf A M et al.. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression.  J Hepatol. 2009;  51(4) 765-777
    CrossrefPubMedGoogle Scholar
  • 73 Lagathu C, Bastard J P, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone.  Biochem Biophys Res Commun. 2003;  311(2) 372-379
    CrossrefPubMedGoogle Scholar
  • 74 Klover P J, Zimmers T A, Koniaris L G, Mooney R A. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice.  Diabetes. 2003;  52(11) 2784-2789
    CrossrefPubMedGoogle Scholar
  • 75 Senn J J, Klover P J, Nowak I A et al.. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes.  J Biol Chem. 2003;  278(16) 13740-13746
    CrossrefPubMedGoogle Scholar
  • 76 Pradhan A D, Manson J E, Rifai N, Buring J E, Ridker P M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.  JAMA. 2001;  286(3) 327-334
    CrossrefPubMedGoogle Scholar
  • 77 Haukeland J W, Damås J K, Konopski Z et al.. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.  J Hepatol. 2006;  44(6) 1167-1174
    CrossrefPubMedGoogle Scholar
  • 78 Cai D, Yuan M, Frantz D F et al.. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.  Nat Med. 2005;  11(2) 183-190
    CrossrefPubMedGoogle Scholar
  • 79 Wieckowska A, Papouchado B G, Li Z, Lopez R, Zein N N, Feldstein A E. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.  Am J Gastroenterol. 2008;  103(6) 1372-1379
    CrossrefPubMedGoogle Scholar
  • 80 El-Assal O, Hong F, Kim W H, Radaeva S, Gao B. IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver.  Cell Mol Immunol. 2004;  1(3) 205-211
    PubMedGoogle Scholar
  • 81 Cressman D E, Greenbaum L E, DeAngelis R A et al.. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.  Science. 1996;  274(5291) 1379-1383
    CrossrefPubMedGoogle Scholar
  • 82 Jin X, Zimmers T A, Perez E A, Pierce R H, Zhang Z, Koniaris L G. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair.  Hepatology. 2006;  43(3) 474-484
    CrossrefPubMedGoogle Scholar
  • 83 Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells.  Hepatology. 2006;  44(6) 1487-1501
    CrossrefPubMedGoogle Scholar
  • 84 Milner K L, van der Poorten D, Xu A et al.. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease.  Hepatology. 2009;  49(6) 1926-1934
    CrossrefPubMedGoogle Scholar
  • 85 Schroeder F, Jolly C A, Cho T H, Frolov A. Fatty acid binding protein isoforms: structure and function.  Chem Phys Lipids. 1998;  92(1) 1-25
    CrossrefPubMedGoogle Scholar
  • 86 Hui X, Li H, Zhou Z et al.. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1.  J Biol Chem. 2010;  285(14) 10273-10280
    CrossrefPubMedGoogle Scholar
  • 87 Wieckowska A, McCullough A J, Feldstein A E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.  Hepatology. 2007;  46(2) 582-589
    CrossrefPubMedGoogle Scholar
  • 88 Feldstein A E, Canbay A, Angulo P et al.. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis.  Gastroenterology. 2003;  125(2) 437-443
    CrossrefPubMedGoogle Scholar
  • 89 Feldstein A E, Gores G J. Apoptosis in alcoholic and nonalcoholic steatohepatitis.  Front Biosci. 2005;  10 3093-3099
    CrossrefPubMedGoogle Scholar
  • 90 Barreyro F J, Kobayashi S, Bronk S F, Werneburg N W, Malhi H, Gores G J. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis.  J Biol Chem. 2007;  282(37) 27141-27154
    CrossrefPubMedGoogle Scholar
  • 91 Masuoka H C, Mott J, Bronk S F et al.. Mcl-1 degradation during hepatocyte lipoapoptosis.  J Biol Chem. 2009;  284(44) 30039-30048
    CrossrefPubMedGoogle Scholar
  • 92 Cazanave S C, Gores G J. Mechanisms and clinical implications of hepatocyte lipoapoptosis.  Clin Lipidol. 2010;  5(1) 71-85
    CrossrefPubMedGoogle Scholar
  • 93 Witek R P, Stone W C, Karaca F G et al.. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.  Hepatology. 2009;  50(5) 1421-1430
    CrossrefPubMedGoogle Scholar
  • 94 Wieckowska A, Zein N N, Yerian L M, Lopez A R, McCullough A J, Feldstein A E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.  Hepatology. 2006;  44(1) 27-33
    CrossrefPubMedGoogle Scholar
  • 95 Younossi Z M, Jarrar M, Nugent C et al.. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).  Obes Surg. 2008;  18(11) 1430-1437
    CrossrefPubMedGoogle Scholar
  • 96 Malik R, Chang M, Bhaskar K et al.. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.  J Gastroenterol Hepatol. 2009;  24(4) 564-568
    CrossrefPubMedGoogle Scholar
  • 97 Diab D L, Yerian L, Schauer P et al.. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.  Clin Gastroenterol Hepatol. 2008;  6(11) 1249-1254
    CrossrefPubMedGoogle Scholar
  • 98 Horoz M, Bolukbas C, Bolukbas F F et al.. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis.  BMC Gastroenterol. 2005;  5 35
    CrossrefPubMedGoogle Scholar
  • 99 Chalasani N, Deeg M A, Crabb D W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis.  Am J Gastroenterol. 2004;  99(8) 1497-1502
    CrossrefPubMedGoogle Scholar
  • 100 Bonnefont-Rousselot D, Ratziu V, Giral P, Charlotte F, Beucler I, Poynard T. Lido Study Group . Blood oxidative stress markers are unreliable markers of hepatic steatosis.  Aliment Pharmacol Ther. 2006;  23(1) 91-98
    CrossrefPubMedGoogle Scholar
  • 101 Mantena S K, King A L, Andringa K K, Eccleston H B, Bailey S M. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases.  Free Radic Biol Med. 2008;  44(7) 1259-1272
    CrossrefPubMedGoogle Scholar
  • 102 Videla L A, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease.  Free Radic Biol Med. 2004;  37(9) 1499-1507
    CrossrefPubMedGoogle Scholar
  • 103 Higuchi H, Grambihler A, Canbay A, Bronk S F, Gores G J. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1.  J Biol Chem. 2004;  279(1) 51-60
    CrossrefPubMedGoogle Scholar
  • 104 Gao D, Wei C, Chen L, Huang J, Yang S, Diehl A M. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease.  Am J Physiol Gastrointest Liver Physiol. 2004;  287(5) G1070-G1077
    CrossrefPubMedGoogle Scholar
  • 105 Albano E, Mottaran E, Occhino G, Reale E, Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis.  Aliment Pharmacol Ther. 2005;  22(Suppl 2) 71-73
    CrossrefPubMedGoogle Scholar
  • 106 Bataller R, Brenner D A. Liver fibrosis.  J Clin Invest. 2005;  115(2) 209-218
    CrossrefPubMedGoogle Scholar
  • 107 Urtasun R, Nieto N. [Hepatic stellate cells and oxidative stress].  Rev Esp Enferm Dig. 2007;  99(4) 223-230
    PubMedGoogle Scholar
  • 108 Sanyal A J, Chalasani N, Kowdley K V NASH CRN et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.  N Engl J Med. 2010;  362(18) 1675-1685
    CrossrefPubMedGoogle Scholar
  • 109 Dryden Jr G W, Deaciuc I, Arteel G, McClain C J. Clinical implications of oxidative stress and antioxidant therapy.  Curr Gastroenterol Rep. 2005;  7(4) 308-316
    CrossrefPubMedGoogle Scholar
  • 110 Di Sario A, Candelaresi C, Omenetti A, Benedetti A. Vitamin E in chronic liver diseases and liver fibrosis.  Vitam Horm. 2007;  76 551-573
    CrossrefPubMedGoogle Scholar
  • 111 Chalasani N P, Sanyal A J, Kowdley K V NASH CRN Research Group et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.  Contemp Clin Trials. 2009;  30(1) 88-96
    CrossrefPubMedGoogle Scholar
  • 112 Nobili V, Manco M, Devito R et al.. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.  Hepatology. 2008;  48(1) 119-128
    CrossrefPubMedGoogle Scholar
  • 113 Feldstein A E, Lopez R, Abu-Rajab Tamimi T et al.. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.  J Lipid Res. 2010;  51(10) 3046-3054
    CrossrefPubMedGoogle Scholar

Ariel FeldsteinM.D. 

Department of Cell Biology, Lerner Research Institute, Cleveland Clinic College of Medicine of CWRU

9500 Euclid Avenue, Cleveland, Ohio 44195

Email: feldsta@ccf.org

      >